Literature DB >> 19430715

Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer.

Takako Eguchi Nakajima1, Yasuhide Yamada, Tetsutaro Hamano, Koh Furuta, Takuji Gotoda, Hitoshi Katai, Ken Kato, Tetsuya Hamaguchi, Yasuhiro Shimada.   

Abstract

PURPOSE: Adipocytokines are adipocyte-secreted hormones associated with some malignancies. We investigated the association of adipocytokines with gastric cancer.
METHODS: The levels of body mass index (BMI) and adiponectin, leptin, resistin, visfatin, and C-peptide in blood at diagnosis were measured in 156 gastric cancer patients and 156 age- and sex-matched controls. Logistic regression models were used to estimate odds ratio, and one-way analysis of variance was performed to examine the prevalence of each variable between 2 or more groups.
RESULTS: Adiponectin, C-peptide and BMI levels were significantly lower, and resistin and visfatin levels were significantly higher in the patients on multivariate analysis (P=0.0004, 0.0006, 0.0051, 0.0006 and 0.0013, respectively). In the controls, the inverse correlation between BMI and adiponectin was comparatively strong, but was weak in the patients. The correlation between BMI and leptin was strong in both the controls and the patients. The correlation between BMI and resistin or visfatin was not clear in either the patients or the controls. The correlation between BMI and C-peptide was not clear in the controls, but might be weak in the patients. Leptin, C-peptide and BMI levels gradually decreased with stage progression, and resistin and visfatin levels gradually increased with stage progression (P<0.0001 for all). Comparison between 38 patients with Stage I gastric cancer and the controls showed that adiponectin level tended to decrease in the patients (P=0.0582), and BMI level was not different between two groups (P=0.2480).
CONCLUSIONS: Resistin and visfatin may be good biomarkers of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430715     DOI: 10.1007/s00535-009-0063-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  18 in total

1.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

2.  Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma.

Authors:  J R Daling; K E Malone; D R Doody; L G Johnson; J R Gralow; P L Porter
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

Review 3.  Insulin, insulin-like growth factors and colon cancer: a review of the evidence.

Authors:  E Giovannucci
Journal:  J Nutr       Date:  2001-11       Impact factor: 4.798

4.  Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study.

Authors:  Esther K Wei; Edward Giovannucci; Charles S Fuchs; Walter C Willett; Christos S Mantzoros
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

5.  Plasma adiponectin and gastric cancer.

Authors:  Makoto Ishikawa; Joji Kitayama; Shinsuke Kazama; Takeyuki Hiramatsu; Kenji Hatano; Hirokazu Nagawa
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

6.  A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization.

Authors:  S E Hufton; P T Moerkerk; R Brandwijk; A P de Bruïne; J W Arends; H R Hoogenboom
Journal:  FEBS Lett       Date:  1999-12-10       Impact factor: 4.124

Review 7.  Obesity and cancer.

Authors:  Eugenia E Calle; Michael J Thun
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

8.  Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer.

Authors:  Nigel B Jamieson; Duncan J F Brown; A Michael Wallace; Donald C McMillan
Journal:  Cytokine       Date:  2004 Jul 21-Aug 7       Impact factor: 3.861

9.  Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system.

Authors:  Maria Dalamaga; Konstantinos Karmaniolas; Athina Nikolaidou; John Chamberland; Alex Hsi; Amalia Dionyssiou-Asteriou; Christos S Mantzoros
Journal:  Eur J Cancer       Date:  2008-08       Impact factor: 9.162

10.  Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers.

Authors:  Barbara E Wolfe; David C Jimerson; Christine Orlova; Christos S Mantzoros
Journal:  Clin Endocrinol (Oxf)       Date:  2004-09       Impact factor: 3.478

View more
  52 in total

1.  Association between dietary carbohydrate intake, glycemic index and glycemic load, and risk of gastric cancer.

Authors:  Yao Ye; Yihua Wu; Jinming Xu; Kefeng Ding; Xiaoyun Shan; Dajing Xia
Journal:  Eur J Nutr       Date:  2016-02-12       Impact factor: 5.614

2.  Effects of resistin-like molecule β over-expression on gastric cancer cells in vitro.

Authors:  Li-Duan Zheng; Chun-Lei Yang; Teng Qi; Meng Qi; Ling Tong; Qiang-Song Tong
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.

Authors:  Hung-Lung Ke; Hui-Hui Lin; Wei-Ming Li; Ching-Chia Li; Lin-Li Chang; Yi-Chen Lee; Chun-Nung Huang; Wen-Jeng Wu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

4.  Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.

Authors:  Bo Tan; Sucai Dong; Robert L Shepard; Lisa Kays; Kenneth D Roth; Sandaruwan Geeganage; Ming-Shang Kuo; Genshi Zhao
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

Review 5.  Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer.

Authors:  Małgorzata Muc-Wierzgoń; Ewa Nowakowska-Zajdel; Sylwia Dzięgielewska-Gęsiak; Teresa Kokot; Katarzyna Klakla; Edyta Fatyga; Elżbieta Grochowska-Niedworok; Dariusz Waniczek; Janusz Wierzgoń
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  Nicotinamide phosphoribosyltransferase in malignancy: a review.

Authors:  Rodney E Shackelford; Kim Mayhall; Nicole M Maxwell; Emad Kandil; Domenico Coppola
Journal:  Genes Cancer       Date:  2013-11

7.  Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.

Authors:  Bo Tan; Debra A Young; Zhao-Hai Lu; Tao Wang; Timothy I Meier; Robert L Shepard; Kenneth Roth; Yan Zhai; Karen Huss; Ming-Shang Kuo; James Gillig; Saravanan Parthasarathy; Timothy P Burkholder; Michele C Smith; Sandaruwan Geeganage; Genshi Zhao
Journal:  J Biol Chem       Date:  2012-12-13       Impact factor: 5.157

8.  Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.

Authors:  Shao-Jie Zhou; Tie-Qiang Bi; Chun-Xin Qin; Xiao-Qing Yang; Kai Pang
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

9.  The association of serum adiponectin levels with histopathological variables in gastric cancer patients.

Authors:  Mesut Seker; Ahmet Bilici; Berkant Sonmez; Bala Basak Oven Ustaalioğlu; Mahmut Gumus; Hulya Gozu; Mehmet Sargin; Asuman Orcun; Cem Gezen; Mehmet Eser; Nejdet Bildik; Taflan Salepci
Journal:  Med Oncol       Date:  2009-12-16       Impact factor: 3.064

10.  Adipocytokines and squamous cell carcinoma of the esophagus.

Authors:  Takako Eguchi Nakajima; Yasuhide Yamada; Tetsutaro Hamano; Koh Furuta; Ichiro Oda; Hoichi Kato; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.